Company with NASH Candidate in Ph IIb Trials Updates $86 Million IPO filing

Cirius Therapeutics has updated it filing for a planned $86 million IPO. The date of the IPO still hasn't been set.

Cirius' lead candidate, MSDC-0602K, is a once daily, oral treatment for NASH. The novel approach targets NASH at the mitochondria level.